<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03493048</url>
  </required_header>
  <id_info>
    <org_study_id>ERBIRINOX-CRCLM</org_study_id>
    <nct_id>NCT03493048</nct_id>
  </id_info>
  <brief_title>Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX For CRCLM</brief_title>
  <official_title>Cetuximab Plus FOLFOXIRI vs Cetuximab Plus FOLFOX in Patients With Initially Unresectable Colorectal Liver Metastasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the trial is to optimize response rates and rates of secondary resections of
      metastases in patients with initially non-resectable metastatic colorectal cancer Liver
      Metastasis of RAS wildtype. The patients will be treated in two therapy groups:

      Experimental arm A: Chemotherapy with FOLFOXIRI + Cetuximab Standard arm B: Chemotherapy with
      FOLFOX + Cetuximab
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall response rate in each cohort</measure>
    <time_frame>up to about 6 month</time_frame>
    <description>RECIST</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Colo-rectal Cancer</condition>
  <condition>Liver Metastases</condition>
  <arm_group>
    <arm_group_label>Cetuximab Plus FOLFOXIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cetuximab Plus FOLFOXIRI Patients will receive Cetuximab Plus FOLFOXIRI every 14 days: Cetuximab 500mg/m2 ivd over 90 minutes on Day 1; Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1; Irinotecan 130 mg/m2 ivd over 90 minutes on Day 1; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cetuximab Plus FOLFOX</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive Cetuximab Plus FOLFOX every 14 days: Cetuximab 500mg/m2 ivd over 90 minutes on Day 1; Oxaliplatin 85 mg/m2 ivd over 3 hours on Day 1; Leucovorin (l-LV) 200mg/m2 ivd over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Irinotecan 130 mg/m²</description>
    <arm_group_label>Cetuximab Plus FOLFOXIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab, iv, 500mg/m2</description>
    <arm_group_label>Cetuximab Plus FOLFOXIRI</arm_group_label>
    <arm_group_label>Cetuximab Plus FOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
    <description>5-FU 2400 mg/m² cont. inf.</description>
    <arm_group_label>Cetuximab Plus FOLFOXIRI</arm_group_label>
    <arm_group_label>Cetuximab Plus FOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>oxaliplatin 85 mg/m²</description>
    <arm_group_label>Cetuximab Plus FOLFOXIRI</arm_group_label>
    <arm_group_label>Cetuximab Plus FOLFOX</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>leucovorin 200 mg/m²</description>
    <arm_group_label>Cetuximab Plus FOLFOXIRI</arm_group_label>
    <arm_group_label>Cetuximab Plus FOLFOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Initially unresectable colorectal liver metastasis confirmed by the multidisciplinary
             team (MDT). Focus on patients with large tumor load at metastatic sites and/or
             symptomatic metastatic disease

          -  Adult patients (≥ 18,&lt;=75 years of age)

          -  RAS wild-type tested in KRAS exon 2 (codons 12/13) KRAS exon 3 (codons 59/61) KRAS
             exon 4 (codons 117/146) NRAS exon 2 (codons 12/13) NRAS exon 3 (codons 59/61) NRAS
             exon 4 (codons 117/146)

          -  At least one measurable lesion according to RECIST measured within 3 weeks prior to
             registration

          -  No previous chemotherapy for metastatic disease (adjuvant chemotherapy for
             non-metastatic disease is allowed if terminated more than 6 months ago)

          -  Performance status ECOG 0-1

          -  Male and female subjects &gt; 18 years of age

          -  Adequate haematological, hepatic, renal and metabolic function parameters: Leukocytes
             &gt; 3000/mm³, ANC ≥ 1500/mm3, platelets ≥ 100,000/mm3, Hb &gt; 9g/dl (may be transfused or
             treated with erythropoietin to maintain or exceed this level)Creatinine clearance ≥ 50
             ml/min or serum creatinine ≤ 1.5 x upper limit of normal Bilirubin ≤ 1.5 x upper limit
             of normal, GOT-GPT ≤ 2.5 x upper limit of normal in absence of liver metastases, or ≤
             5 x upper limit of normal in presence of liver metastases, AP ≤ 5 x upper limit of
             normal Magnesium ≥ lower limit of normal; calcium ≥ lower limit of normal (may be
             substituted to maintain or exceed this level)

          -  Negative pregnancy test and willingness to use highly effective methods of
             contraception (per institutional standard) during treatment and for 6 months (male or
             female) after the end of treatment (adequate: oral contraceptives, intrauterine device
             or barrier method in conjunction with spermicidal jelly).

          -  Before subject registration, written informed consent must be given according to local
             regulations.

        Exclusion Criteria:

          -  Past or current history of malignancies except for the indication under this study and
             curatively treated:

          -  Basal and squamous cell carcinoma of the skin

          -  In-situ carcinoma of the cervix

          -  Other malignant disease without recurrence after at least 5 years of follow-up
             Clinically significant cardiovascular disease in (incl. myocardial infarction,
             unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac
             arrhythmia) ≤ 6 months before enrolment.

          -  Clinically relevant interstitial lung disease, e.g. pneumonitis or pulmonary fibrosis
             or evidence of interstitial lung disease on baseline chest CT scan.

          -  History of evidence upon physical examination of CNS disease unless adequately treated
             (e.g. primary brain tumour, seizure not controlled with standard medical therapy,
             brain metastases or history of stroke).

          -  Pre-existing neuropathy &gt; grade 1 (NCI CTCAE), except for loss of tendon reflex
             Allogeneic transplantation requiring immunosuppressive therapy.

          -  Severe non-healing wounds, ulcers or bone fractions.

          -  Evidence of bleeding diathesis or coagulopathy.

          -  Patients not receiving therapeutic anticoagulation must have an INR &lt; 1,5 ULN and aPTT
             &lt; 1,5 ULN within 7 days prior to randomization. The use of full dose anticoagulants is
             allowed as long as the INR or aPTT is within therapeutic limits (according to the
             medical standard in the institution) and the patient has been on a stable dose for
             anticoagulants for at least two weeks at the time of randomisation.

          -  Concomitant therapy with certain anti-viral medicines (sorivudine and brivudine or
             analogue compounds).

          -  Major surgical procedure, open biopsy, nor significant traumatic injury within 28 days
             prior to study treatment start, or anticipation of the need for major surgical
             procedure during the course of the study except for surgery for colorectal cancer with
             curative intent and central venous line placement for chemotherapy administration.

          -  Pregnancy or breastfeeding women.

          -  Subjects with known allergy to the study drugs or to any of its excipients.

          -  Known DPD deficiency.

          -  Current or recent (within the 28 days prior to starting study treatment) treatment of
             another investigational drug or participation in another investigational study.

          -  Known grade III/IV allergic reaction against monoclonal antibodies.

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study protocol and follow-up schedule; those conditions
             should be discussed with the subject before registration in the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Li Yuhong, MD</last_name>
      <phone>020-87342487</phone>
      <email>liyh@sysucc.org.cn</email>
    </contact>
    <investigator>
      <last_name>Li Yuhong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 27, 2018</study_first_submitted>
  <study_first_submitted_qc>April 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 10, 2018</study_first_posted>
  <last_update_submitted>April 9, 2018</last_update_submitted>
  <last_update_submitted_qc>April 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Yuhong Li</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

